Cold agglutinin disease revisited: a multinational, observational study of 232 patients von Berentsen, Sigbjørn, Barcellini, Wilma, D'Sa, Shirley, Randen, Ulla, Tvedt, Tor Henrik Anderson, Fattizzo, Bruno, Haukås, Einar, Kell, Megan, Brudevold, Robert, Dahm, Anders E.A., Dalgaard, Jakob, Frøen, Hege, Hallstensen, Randi Fykse, Jæger, Pernille H., Hjorth-Hansen, Henrik, Małecka, Agnieszka, Oksman, Markku, Rolke, Jürgen, Sekhar, Mallika, Sørbø, Jon Hjalmar, Tjønnfjord, Eirik, Tsykunova, Galina, Tjønnfjord, Geir E.

Volltext

TKI safety von Hjorth‐Hansen, Henrik

Volltext

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study von Flygt, Hjalmar, Söderlund, Stina, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Mustjoki, Satu, Majeed, Waleed, Lübking, Anna, Dreimane, Arta, Markevärn, Berit, Stenke, Leif, Myhr Eriksson, Kristina, Gjertsen, Bjørn Tore, Gedde‐Dahl, Tobias, Dimitrijevic, Andreja, Udby, Lene, Olsson‐Strömberg, Ulla, Hjorth‐Hansen, Henrik

Volltext

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML von Warfvinge, Rebecca, Geironson, Linda, Sommarin, Mikael N.E., Lang, Stefan, Karlsson, Christine, Roschupkina, Teona, Stenke, Leif, Stentoft, Jesper, Olsson-Strömberg, Ulla, Hjorth-Hansen, Henrik, Mustjoki, Satu, Soneji, Shamit, Richter, Johan, Karlsson, Göran

Volltext

A patient with minimal myeloma treatment who survived for 20 years von Behsen, Alenka Djarmila, Vandsemb, Esten Nymoen, Slørdahl, Tobias Schmidt, Hjorth-Hansen, Henrik, Quist-Paulsen, Petter, Misund, Kristine, Sponaas, Anne-Marit, Waage, Anders

Volltext

Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life–Lite Clinical Trials Version (IWQOL‐Lite‐CT) von Kolotkin, Ronette L., Williams, Valerie S. L., von Huth Smith, Lisa, Meincke, Henrik Hjorth, Qin, Shanshan, Williams, Nicole, Fehnel, Sheri E.

Volltext

The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses von Christiansson, Lisa, Söderlund, Stina, Mangsbo, Sara, Hjorth-Hansen, Henrik, Höglund, Martin, Markevärn, Berit, Richter, Johan, Stenke, Leif, Mustjoki, Satu, Loskog, Angelica, Olsson-Strömberg, Ulla

Volltext

S155: PROGNOSTIC FACTORS FOR 3‐YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO‐SKI) TRIAL von Pfirrmann, Markus, Mahon, Francois‐Xavier, Dulucq, Stéphanie, Hochhaus, Andreas, Panayiotidis, Panayiotis, Almeida, Antonio, Mayer, Jiri, Hjorth‐Hansen, Henrik, Janssen, Jeroen J. W. M., Mustjoki, Satu, Martinez‐Lopez, Joaquín, Vestergaard, Hanne, Ehrencrona, Hans, Kairisto, Veli, Machová Poláková, Kateřina, Emmanuel Nicolini, Franck, Hofmann, Wolf‐Karsten, Guilhot, Joëlle, Saussele, Susanne, Richter, Johan

Volltext

Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response von Warfvinge, Rebecca, Geironson Ulfsson, Linda, Dhapola, Parashar, Safi, Fatemeh, Sommarin, Mikael, Soneji, Shamit, Hjorth-Hansen, Henrik, Mustjoki, Satu, Richter, Johan, Thakur, Ram Krishna, Karlsson, Göran

Volltext

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia von Huuhtanen, Jani, Ilander, Mette, Yadav, Bhagwan, Dufva, Olli M.J., Lähteenmäki, Hanna, Kasanen, Tiina, Klievink, Jay, Olsson-Strömberg, Ulla, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Höglund, Martin, Söderlund, Stina, Dreimane, Arta, Porkka, Kimmo, Gedde-Dahl, Tobias, Gjertsen, Björn T., Stenke, Leif, Myhr-Eriksson, Kristina, Markevärn, Berit, Lübking, Anna, Dimitrijevic, Andreja, Udby, Lene, Bjerrum, Ole Weis, Hjorth-Hansen, Henrik, Mustjoki, Satu

Volltext

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia von Porkka, Kimmo, Koskenvesa, Perttu, Lundán, Tuija, Rimpiläinen, Johanna, Mustjoki, Satu, Smykla, Richard, Wild, Robert, Luo, Roger, Arnan, Montserrat, Brethon, Benoit, Eccersley, Lydia, Hjorth-Hansen, Henrik, Höglund, Martin, Klamova, Hana, Knutsen, Håvar, Parikh, Suhag, Raffoux, Emmanuel, Gruber, Franz, Brito-Babapulle, Finella, Dombret, Hervé, Duarte, Rafael F., Elonen, Erkki, Paquette, Ron, Zwaan, C.Michel, Lee, Francis Y.F.

Volltext

S159: HEALTH‐RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO‐SKI STUDY von Efficace, Fabio, Mahon, Francois‐Xavier, Richter, Johan, Piciocchi, Alfonso, Cipriani, Marta, Nicolini, Franck Emmanuel, Hjorth‐Hansen, Henrik, Almeida, Antonio, Janssen, Jeroen J. W. M., Mayer, Jiri, Koskenvesa, Perttu, Panayiotidis, Panayiotis, Olsson‐Strömberg, Ulla, Martinez‐Lopez, Joaquín, Rousselot, Philippe, Vestergaard, Hanne, Ehrencrona, Hans, Kairisto, Veli, Polakova, Katerina Machova, Mustjoki, Satu, Berger, Marc, Hochhaus, Andreas, Pfirrmann, Markus, Saussele, Susanne

Volltext

High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease von Berentsen, Sigbjørn, Randen, Ulla, Vågan, Anne Marita, Hjorth-Hansen, Henrik, Vik, Anders, Dalgaard, Jakob, Jacobsen, Eva-Marie, Thoresen, Aud S., Beiske, Klaus, Tjønnfjord, Geir E.

Volltext

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study von Baccarani, Michele, Rosti, Gianantonio, Castagnetti, Fausto, Haznedaroglu, Ibrahim, Porkka, Kimmo, Abruzzese, Elisabetta, Alimena, Giuliana, Ehrencrona, Hans, Hjorth-Hansen, Henrik, Kairisto, Veli, Levato, Luciano, Martinelli, Giovanni, Nagler, Arnon, Lanng Nielsen, Johan, Ozbek, Ugur, Palandri, Francesca, Palmieri, Fausto, Pane, Fabrizio, Rege-Cambrin, Giovanna, Russo, Domenico, Specchia, Giorgina, Testoni, Nicoletta, Weiss-Bjerrum, Ole, Saglio, Giuseppe, Simonsson, Bengt

Volltext

Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro von Jönsson, Sofia, Hjorth-Hansen, Henrik, Olsson, Bob, Wadenvik, Hans, Sundan, Anders, Standal, Therese

Volltext

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia von El Missiry, Mohamed, Hjorth-Hansen, Henrik, Richter, Johan, Olson-Strömberg, Ulla, Stenke, Leif, Porkka, Kimmo, Kreutzman, Anna, Mustjoki, Satu

Volltext

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting von Landberg, Niklas, von Palffy, Sofia, Askmyr, Maria, Lilljebjörn, Henrik, Sandén, Carl, Rissler, Marianne, Mustjoki, Satu, Hjorth-Hansen, Henrik, Richter, Johan, Ågerstam, Helena, Järås, Marcus, Fioretos, Thoas

Volltext

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line von Kreutzman, Anna, Yadav, Bhagwan, Brummendorf, Tim H., Gjertsen, Bjorn Tore, Hee Lee, Moon, Janssen, Jeroen, Kasanen, Tiina, Koskenvesa, Perttu, Lotfi, Kourosh, Markevärn, Berit, Olsson-Strömberg, Ulla, Stentoft, Jesper, Stenke, Leif, Söderlund, Stina, Udby, Lene, Richter, Johan, Hjorth-Hansen, Henrik, Mustjoki, Satu

Volltext

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled... von Gimsing, Peter, Dr, Carlson, Kristina, DMSci, Turesson, Ingemar, DMSci, Fayers, Peter, Prof, Waage, Anders, Prof, Vangsted, Annette, MD, Mylin, Anne, MD, Gluud, Christian, DMSci, Juliusson, Gunnar, Prof, Gregersen, Henrik, PhD, Hjorth-Hansen, Henrik, DMSci, Nesthus, Ingerid, MD, Dahl, Inger Marie S, Prof, Westin, Jan, DMSci, Nielsen, Johan Lanng, DMSci, Knudsen, Lene Meldgaard, DMSci, Ahlberg, Lucia, MD, Hjorth, Martin, DMSci, Abildgaard, Niels, Prof, Andersen, Niels Frost, MD, Linder, Olle, MD, Wisløff, Finn, Prof

Volltext

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006) von Hjorth-Hansen, Henrik, Stenke, Leif, Söderlund, Stina, Dreimane, Arta, Ehrencrona, Hans, Gedde-Dahl, Tobias, Gjertsen, Bjørn Tore, Höglund, Martin, Koskenvesa, Perttu, Lotfi, Kourosh, Majeed, Waleed, Markevärn, Berit, Ohm, Lotta, Olsson-Strömberg, Ulla, Remes, Kari, Suominen, Merja, Simonsson, Bengt, Porkka, Kimmo, Mustjoki, Satu, Richter, Johan

Volltext